GlassScriptPhysician profile
Thomas Michael Koroscil
NPI 1811953680
$7,467.78
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,195 · 2020: $1,100 · 2021: $1,573 · 2022: $1,403 · 2023: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,896.00 | 2019-2023 | Repatha, Evenity, Prolia |
| Abbott Laboratories | $708.64 | 2019-2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $466.18 | 2019-2023 | Korlym |
| Lilly USA, LLC | $451.28 | 2019-2023 | Mounjaro, Humulin, Trulicity |
| Pfizer INC. | $366.43 | 2019-2023 | |
| Novo Nordisk INC | $342.57 | 2019-2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $339.86 | 2019-2022 | |
| Amarin Pharma, INC. | $220.01 | 2019-2020 | |
| Abbvie INC. | $208.52 | 2019-2023 | |
| Shire North American Group INC | $207.48 | 2019 | |
| Horizon Therapeutics Plc | $198.07 | 2020-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $197.30 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $193.35 | 2019-2021 | |
| Radius Health, INC. | $190.70 | 2019-2023 | Tymlos |
| Xeris Pharmaceuticals, INC. | $190.24 | 2020-2023 | Recorlev, Gvoke Hypopen |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $168.95 | 2022-2023 | Strensiq |
| Antares Pharma, INC. | $145.34 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $107.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.12 | 2019-2022 | |
| Eisai INC. | $89.64 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $83.76 | 2020-2022 | |
| Insulet Corporation | $77.93 | 2019-2023 | Omnipod |
| Amryt Pharma Holdings LTD | $69.63 | 2022-2023 | Mycapssa |
| Medtronic, INC. | $58.71 | 2022-2023 | Minimed 770g |
| Ipsen Biopharmaceuticals, INC | $56.36 | 2020-2023 | Somatuline Depot |
| Tandem Diabetes Care, INC. | $55.26 | 2022 | |
| Ibsa Pharma INC. | $54.64 | 2021-2023 | Tirosint, Licart |
| Halozyme INC | $40.39 | 2023 | |
| Ascendis Pharma Endocrinology INC | $31.61 | 2023 | |
| Dexcom, INC. | $30.04 | 2019-2023 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $28.48 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $28.41 | 2023 | Isturisa |
| Takeda Pharmaceuticals U.S.A., INC. | $21.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.88 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Koroscil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.